Healthcare / Medical Instruments & SuppliesShanghai
$7.68
-0.02 (-0.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $211.6M · quality 76.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.4B
P/E
14.5x
↓EV/EBITDA
7.1x
↓ROE
8.9%
↑Gross Margin
33.1%
↓Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-9.7%
FCF CAGR
+16.5%
FCF margin
11.4%
FCF / Net income
1.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.30B · net income $240.3M · FCF $261.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.30B | $2.30B | $2.26B | $2.45B | $3.12B |
| Net Income | $240.3M | $240.3M | $215.3M | $230.9M | $311.7M |
| EBITDA | $481.6M | $481.6M | $440.1M | $488.4M | $585.1M |
| EPS | 0.55 | 0.55 | 0.49 | 0.53 | 0.71 |
| Gross Margin | 33.1% | 33.1% | 32.5% | 32.5% | 33.7% |
| Operating Margin | 12.7% | 12.7% | 11.1% | 12.1% | 12.7% |
| Net Margin | 10.5% | 10.5% | 9.5% | 9.4% | 10.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | 0.25 | 0.33 | 0.35 |
| Current Ratio | 1.88 | 1.88 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $261.1M | $261.1M | $148.9M | $211.6M | $165.3M |
| Returns | |||||
| ROE | 8.9% | 8.9% | 8.5% | 9.6% | 14.0% |
| Valuation | |||||
| P/E | 14.49 | 14.49 | 14.16 | 17.51 | 20.70 |
| EV/EBITDA | 7.10 | 7.10 | 7.54 | 8.88 | 11.64 |
| P/B | 1.24 | 1.24 | 1.20 | 1.68 | 2.89 |
| Growth & Yield | |||||
| Revenue Growth | 1.6% | 1.6% | -7.8% | -21.4% | — |
| EPS Growth | 12.2% | 12.2% | -7.5% | -25.4% | — |
| Dividend Yield | 2.2% | 2.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
7.4%
EPS terminal req.
$0.68
Spread vs growth
4.8%
5Y implied EPS CAGR
8.4%
EPS terminal req.
$0.82
Spread vs growth
3.8%
10Y implied EPS CAGR
9.2%
EPS terminal req.
$1.33
Spread vs growth
3.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+5.2%
Start / end P/E
15.2x → 14.0x
EPS bridge
0.49 → 0.55
Residual
-1.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.